Lenalidomide Stada

Lenalidomide, the active ingredient in Lenalidomide Stada, is an immunomodulatory agent presented as a strength/form for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is an immunomodulatory antineoplastic used in several hematologic malignancies.

Multiple Myeloma: improves disease control and prolongs survival in relapsed or refractory patients. Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. Mantle Cell Lymphoma: provides therapeutic benefit in relapsed or refractory disease.

Lenalidomide may cause a range of adverse reactions.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often self‑limiting. - Rash: skin irritation or erythema. - Cytopenias: reduced neutrophils, platelets or red cells. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism. - Secondary primary malignancies. - Severe neutropenia or febrile neutropenia. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating therapy, several safety considerations are required.

Pregnancy contraindication: drug is classified as Category X; avoid use in pregnant women. Thromboembolic risk: assess need for prophylactic anticoagulation. Hematologic monitoring: regular CBCs to detect cytopenias. Renal impairment: dose adjustment may be necessary in reduced kidney function. Drug interaction vigilance: review concomitant medications for CYP3A4 modulators. Store at room temperature: keep in original packaging, protect from moisture and light.

Lenalidomide can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) – may lower lenalidomide exposure. - P‑gp inducers – can reduce absorption and efficacy. - Concurrent use with other immunomodulatory agents – increased risk of hematologic toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole) – may raise plasma levels. - NSAIDs – heightened risk of renal impairment. - Live vaccines – reduced efficacy and potential infection risk.